Comorbid cancer in Parkinson's disease

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1809-1817

  Lo, Raymond Y ^a,b   Tanner, Caroline M ^b   Van Den Eeden, Stephen K ^c   Albers, Kathleen B ^c   Leimpeter, Amethyst D ^c   Nelson, Lorene M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

Cancer; Comorbidity; Epidemiology; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; COLORECTAL CANCER; COMORBIDITY; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PARKINSON DISEASE; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; SMOKING; UNITED STATES;

AGED; CALIFORNIA; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 77956805341     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23246     Document Type: Article

References (41)

1. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson's disease and cancer. Trends Neurosci 2005;28:348-352.
2. Doshay LJ. Problem situations in the treatment of paralysis agitans. J Am Med Assoc 1954;156:680-684.
3. Westlund K, Hougen A. Cancer as a cause of death among patients with other chronic disease (letter). J Am Med Assoc 1956;162:1003.
4. Barbeau A, Joly JG. Parkinsonism and cancer. Union Med Can 1963;92:169-174.
5. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
6. Pritchard PB, III, Netsky MG. Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 1973;23:215-222.
7. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983;40:151-154. (Pubitemid 13139115)
8. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-509.
9. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-232.
10. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-1868.
11. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299.
12. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1501.
13. Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 1998;97:20-26.
14. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 1999;52:395-398.
15. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000;247:429-434. (Pubitemid 30433556)
16. Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002;13:157-164. (Pubitemid 34160490)
17. D'Amelio M, Ragonese P, Morgante L, et al. Tumor diagnosis preceding Parkinson's disease: a case-control study. Mov Disord 2004;19:807-811.
18. Elbaz A, Peterson BJ, Bower JH, et al. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 2005;20:719-725.
19. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
20. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson's disease. Epidemiology 2006;17:582-587.
21. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007;18:705-711. (Pubitemid 46988238)
22. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007;16:1260-1265. (Pubitemid 46984968)
23. Constantinescu R, Romer M, Kieburtz K. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 2007;22:720-722. (Pubitemid 46800147)
24. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007;22:1252-1257.
25. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
26. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson's disease. Arch Neurol 2007;64:990-997.
27. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-710.
28. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
29. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
30. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
31. SEER Site Recode ICD-O-3 (1/27/2003) Definition. Available at: http://seer.cancer.gov/siterecode/icdo3-d01272003/.
32. Office of the Surgeon General USDoHHS. The Health Consequences of Smoking: A Report of the Surgeon General 017-023-00211-2. 2004. p 39-326.
33. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972;93:556-561.
34. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003;9:321-327.
35. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006;166:1907-1914. (Pubitemid 44455175)
36. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009;65:76-82.
37. Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003;14:847-857.
38. Odenbro A, Gillgren P, Bellocco R, Boffetta P, Hakansson N, Adami J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007;156:99-105.
39. Louis ED, Pellegrino KM, Factor-Litvak P, et al. Cancer and blood concentrations of the comutagen harmane in essential tremor. Mov Disord 2008;23:1747-1751.
40. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
41. Ferreira J, Silva JM, Freire R, et al. Skin cancers and precancerous lesions in Parkinson's disease patients. Mov Disord 2007;22:1471-1475.